Core Viewpoint - The company is conducting a private placement of shares to raise funds for long-term strategic development, addressing investor concerns regarding potential misuse of funds and the impact on shareholder equity [1] Group 1: Fundraising Details - The total amount to be raised through the private placement is not exceeding 1,007.54 million yuan [1] - The funds will primarily be allocated to three projects: Smart Elderly Care Project, Phase II of the Proton Therapy Center, and working capital supplementation [1] Group 2: Project Allocations - The Smart Elderly Care Project has a total investment of approximately 751 million yuan, with about 638 million yuan planned to be raised, aimed at capitalizing on the "silver economy" [1] - The Phase II Proton Therapy Center project has a total investment of 99.93 million yuan, with the entire amount to be funded through the private placement, targeting the gap in the proton therapy market in Northwest China [1] - The working capital supplementation is set at 270 million yuan, intended to optimize the company's capital structure and enhance ongoing operational capabilities [1] Group 3: Strategic Intent - The private placement aligns with national policies and is a proactive choice based on the company's development strategy, aiming to seize industry growth opportunities and improve asset utilization [1] - The company emphasizes its commitment to maintaining proper operations and protecting the legal rights of all shareholders, particularly minority shareholders [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Taihe Oncology Hospital Proton Therapy Center, has officially operated for one year since December 16, 2024, emphasizing its commitment to enhancing clinical capabilities and international collaboration in proton therapy [1] Group 1: Operational Performance - The Guangzhou Proton Therapy Center has fully utilized its four treatment rooms, providing proton therapy services to a total of 550 patients, with over 80 new patients added each month [1] - The center's patient demographic spans across 31 provincial administrative regions in China and over 20 countries and regions, with patients ranging in age from 1 to 91 years old [1] - The center completed China's first proton therapy for choroidal malignant melanoma in July 2025, marking a significant milestone in its operational achievements [1] Group 2: Strategic Development - The company is focused on strengthening its core competitiveness in high-end medical services through continuous optimization of service processes and improvement of treatment efficiency [1] - The steady advancement of the proton therapy business has further enhanced the company's layout in the field of precision cancer treatment [1] - Future plans include ongoing enhancements in clinical capabilities and collaboration with advanced international medical institutions to keep pace with global developments in proton therapy technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院質子治療中心（以下簡稱「廣州 醫院質子中心」）自2024年12月16日起至今，已正式運營一周年。公司高度重視 質子治療中心的臨床能力建設，堅持加強與國際先進醫療機構合作科研，與國際 質子治療技術同步發展，通過引進高端醫療人才、加強技術研發與學術交流等方 式，持續提升診療水平。截至目前，廣州醫院質子中心的臨床服務能力已得到充 分驗證，各項運營指標表現良好。 廣州醫院質子中心四間質子治療室已經全部啟用，累計為550位患者提供質子治 療服務，單月新增患者超過80人，服務能力持續提升。服務患者範圍覆蓋國內31 個省級行政區以及20多個國家和地區，接受質子治療的患者年齡從1歲至91歲。 2025年7月，廣州醫 ...

Core Viewpoint - International Medicine (000516.SZ) plans to raise up to 1.008 billion yuan through a private placement, focusing on three main areas: smart healthcare projects, proton therapy center phase II, and working capital supplementation [2][4] Group 1: Fundraising and Investment Focus - The fundraising will allocate 638 million yuan to smart healthcare projects, nearly 100 million yuan to the proton therapy center phase II, and 270 million yuan for working capital [2] - The smart healthcare project aims to utilize idle assets to "activate stock assets," responding to both policy demands and the need for asset revitalization [2][5] - The company intends to use 270 million yuan from the fundraising to meet operational funding needs and optimize its capital structure [2][5] Group 2: Financial Challenges - As of September 30, 2025, the company's debt-to-asset ratio reached 68.80%, significantly higher than the industry average, with a sharp decline in cash reserves from 1.52 billion yuan at the end of 2021 to 331 million yuan [4][7] - The company has substantial short-term borrowings of 995 million yuan and non-current liabilities due within a year totaling 905 million yuan, leading to a total of nearly 1.9 billion yuan in rigid debt due within a year [4] - The company has faced significant losses over the past four years, with cumulative losses reaching 2.621 billion yuan [7] Group 3: Market Opportunities and Strategic Adjustments - The company views the fundraising as a strategic adjustment to address market changes, financial pressures, and idle assets [3] - The smart healthcare project and proton therapy center phase II are seen as key initiatives to capitalize on the "silver economy" and high-end medical development opportunities [4][6] - The proton therapy center phase II aims to fill a market gap in the northwest region, where no proton therapy centers are currently operational [6] Group 4: Operational Efficiency and Cost Management - The company is attempting to improve operational efficiency through clinical pathway management and cost structure optimization [8][9] - As of the third quarter of 2025, the company reported a management expense ratio of 10.99%, a decrease from previous periods, indicating initial success in cost control [8] - The company plans to continue enhancing service quality and patient experience while exploring various specialized medical fields to build competitive advantages [9]

Core Viewpoint - The company, International Medicine, plans to raise up to 1.008 billion yuan through a private placement of shares, with the funds allocated for smart healthcare projects, the second phase of the proton therapy center, and to supplement working capital [1][2]. Group 1: Fundraising and Project Allocation - The fundraising will support the transition of the company's business from traditional medical services to high-end radiation therapy, establishing a synergistic business model of "comprehensive diagnosis + precise radiation therapy" [1]. - A significant portion of the raised funds will be directed towards the smart healthcare project, utilizing idle spaces to enhance asset utilization and generate high-value healthcare services [1]. - The second phase of the proton therapy center aims to establish the first operational proton therapy project in Northwest China [2]. Group 2: Financial Performance and Debt Management - The company has experienced substantial losses over recent years, with cumulative losses of 2.621 billion yuan from 2021 to 2024 [3]. - In the first three quarters of 2025, the company reported a revenue of 2.995 billion yuan, a year-on-year decline of 16.94%, and a net loss of 294 million yuan, representing a 38.45% increase in losses compared to the previous year [3]. - The company has a high debt ratio of 68.80%, and the fundraising is expected to help reduce this ratio and optimize the capital structure [1].

Core Insights - The Guangzhou Taihe Tumor Hospital Proton Therapy Center, under Meizhong Jiahe (02453.HK), ranked third in the "2024-2025 China Proton and Heavy Ion Center Rankings," highlighting its excellence in the field of proton therapy [1] Group 1: Rankings and Recognition - The ranking is based on a comprehensive indicator system centered around patient needs and operational excellence, developed with input from 21 experts with over 20 years of experience in radiation therapy [1] - The top two centers in the ranking are Shandong Provincial Tumor Hospital Proton Center and Shanghai Proton and Heavy Ion Hospital [1] Group 2: Equipment and Technology - Guangzhou Taihe Tumor Hospital is equipped with the latest Varian ProBeam proton therapy system, which offers advanced intensity-modulated proton therapy (IMPT) [2] - The superconducting cyclotron can accelerate proton beams to 60.84% of the speed of light, with a wide energy adjustment range for treating tumors at various depths [2] - The pencil beam scanning treatment head allows for precise irradiation with a minimum proton beam diameter of 3mm, minimizing damage to healthy tissue [2] Group 3: Medical Team and Clinical Capabilities - The medical team consists of leading experts in proton therapy, including key authors of the first "Proton and Heavy Ion Therapy Guidelines" in China, with extensive clinical and research experience [2] - The hospital has successfully treated a diverse patient population, with conditions ranging from nasopharyngeal cancer to pancreatic cancer, achieving significant treatment outcomes [3] Group 4: Compliance and Quality Control - The hospital adheres to strict compliance and quality control measures, guided by MD Anderson Cancer Center protocols and national clinical practice guidelines [3] - Comprehensive evaluations and assessments are conducted at every stage of treatment to ensure safety and quality in proton therapy applications [3] Group 5: Patient Experience - The hospital emphasizes a patient-centered service model, featuring case managers who provide detailed explanations of treatment processes and ongoing support throughout the treatment journey [4] - Post-treatment, case managers develop rehabilitation plans and conduct long-term follow-ups to ensure continuous health support for patients [4] Group 6: Future Outlook - The recognition of Guangzhou Taihe Tumor Hospital marks a significant milestone in its development and underscores Meizhong Jiahe's strong capabilities and strategic positioning in the oncology healthcare market [4] - The combination of advanced technology, expert teams, and growing market demand for high-end cancer treatment services positions Meizhong Jiahe for continued competitive advantage and growth opportunities [4]